<DOC>
	<DOCNO>NCT00335777</DOCNO>
	<brief_summary>This research study look Migranal ( study drug ) treatment two migraine attack patient history cutaneous allodynia ( pronounced q-tay-nee-us al-o-din-ee-a ) . Cutaneous allodynia increase skin sensitivity experience headache . It note several study patient migraine , seventy nine percent patient experience allodynia facial skin side headache . Understanding allodynia may help u understand pain system work migraine . This study compare difference , , attack treat early study drug ( 1-hour onset ) attack treat later ( 4-hours ) . You ask treat one attack early one attack late study . If first attack treat early ( 1 hour follow onset throb pain ) second attack treat late ( 4 hour follow onset throb pain ) . It hop study provide information use Migranal subject cutaneous allodynia . The result study may use development large clinical trial . The study drug medication take form nasal spray .</brief_summary>
	<brief_title>A Research Study Examining Migranal Skin Sensitivity Subjects With Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Dihydroergotamine</mesh_term>
	<criteria>Male female subject age 18 65 , inclusive Subjects diagnose episodic migraine , without aura accord IHS ( International Headache Society ) criterion ( Appendix B ) least oneyear prior screen Subjects experience 310 migraine attack ( inclusive ) per month ( previous 6 month ) 15 day headache per month . Subjects report migraine pain quality pulsating/ throb . Subject experience episodic migraine associate cutaneous allodynia , determine Cutaneous Allodynia screen tool investigator . Subject use agrees use duration participation medically acceptable form contraception ( determined investigator ) , female childbearing potential Subjects able understand comply study procedure . Subject provide write informed consent prior screen procedure conduct Pregnant and/or lactate woman Subjects , investigator opinion , history evidence medical psychiatric condition would expose increase risk significant adverse event would interfere assessment efficacy tolerability trial Subjects abnormal ECG , investigator opinion , would expose increase risk adverse event interfere study drug and/or analysis efficacy/tolerability Subjects currently use , expect use trial , CYP 3A4 ( CYP3A4 enzyme ) inhibitor ( protease inhibitor macrolide antibiotic ) Subjects severely impaired hepatic renal function , determine investigator Subjects participate investigational drug trial 30 day prior screen visit Subjects currently history basilar hemiplegic migraine Subjects previously show hypersensitivity ergot alkaloids Subjects history nonresponse DHE45 ( dihydroergotamine ) MigranalÂ® , determine investigator Subjects uncontrolled hypertension Subjects currently history ischemia and/or vasospastic coronary artery disease Subjects , investigator opinion , significant risk factor coronary artery disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>